ReviewMalaria journal2018
Plasmodium vivax molecular diagnostics in community surveys: pitfalls and solutions.
Review in Malaria journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 68 citations in OpenAlex.
- Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages.Nature communications · 2025Trial
- Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.The Lancet. Microbe · 2022Trial
- Genome-wide characterization of Plasmodium vivax infections in local travelers and non-travelers from the Peruvian Amazon.Research square · 2026Article
- High-AltitudeOpen forum infectious diseases · 2026Article
- Review
- Article
- First field evaluation of novel LDH- and HRP2-based rapid tests for Plasmodium vivax and Plasmodium falciparum malaria diagnosis.PLoS neglected tropical diseases · 2025Article
- Prevalence of Asymptomatic non-Falciparum and Falciparum Malaria in the 2014-15 Rwanda Demographic Health Survey.medRxiv : the preprint server for health sciences · 2025Article
- Asymptomatic malaria reservoirs are the last challenge in the elimination in Cambodia.Malaria journal · 2025Article
- Prevalence of asymptomatic non-falciparum and falciparum malaria in the 2014-15 Rwanda Demographic Health Survey.PloS one · 2025Article
- Plasmodium vivax genomic surveillance in the Peruvian Amazon with Pv AmpliSeq assay.PLoS neglected tropical diseases · 2024Article
- Tracing the origins of Plasmodium vivax resurgence after malaria elimination on Aneityum Island in Vanuatu.Communications medicine · 2024Article
- Population genomic evidence of structured and connectedEcology and evolution · 2024Article
- Enhancing malaria detection in resource-limited areas: A high-performance colorimetric LAMP assay for Plasmodium falciparum screening.PloS one · 2024Article
- Malaria in areas under mining activity in the Amazon: A review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Review
- A digital microscope for the diagnosis of Plasmodium falciparum and Plasmodium vivax, including P. falciparum with hrp2/hrp3 deletion.PLOS global public health · 2024Article
- Simultaneous targeted amplicon deep sequencing and library preparation for a time and cost-effective universal parasite diagnostic sequencing approach.Parasitology research · 2023Article
- A cross-sectional study to ascertain malaria prevalence among asymptomatic travellers arriving on the Lihir Group of Islands, Papua New Guinea: implications for elimination efforts.Malaria journal · 2023Article
- Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region.The American journal of tropical medicine and hygiene · 2022Article
- Heterogeneity in prevalence of subclinical Plasmodium falciparum and Plasmodium vivax infections but no parasite genomic clustering in the Chittagong Hill Tracts, Bangladesh.Malaria journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
A distinctive feature of Plasmodium vivax infections is the overall low parasite density in peripheral blood. Thus, identifying asymptomatic infected individuals in endemic communities requires diagnostic tests with high sensitivity. The detection limits of molecular diagnostic tests are primarily defined by the volume of blood analysed and by the copy number of the amplified molecular marker serving as the template for amplification. By using mitochondrial DNA as the multi-copy template, the detection limit can be improved more than tenfold, compared to standard 18S rRNA targets, thereby allowing detection of lower parasite densities. In a very low transmission area in Brazil, application of a mitochondrial DNA-based assay increased prevalence from 4.9 to 6.5%. The usefulness of molecular tests in malaria epidemiological studies is widely recognized, especially when precise prevalence rates are desired. Of concern, however, is the challenge of demonstrating test accuracy and quality control for samples with very low parasite densities. In this case, chance effects in template distribution around the detection limit constrain reproducibility. Rigorous assessment of false positive and false negative test results is, therefore, required to prevent over- or under-estimation of parasite prevalence in epidemiological studies or when monitoring interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.